Soleno Therapeutics, Inc. (SLNO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Redwood City, CA, アメリカ. 現CEOは Anish Bhatnagar.
SLNO を有する IPO日 2014-11-13, 115 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $2.72B.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
